Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.

Over the past several years, 7 trials have examined erlotinib and gefitinib compared with chemotherapy for the treatment of lung cancer patients with 

 mutations. These studies have all shown progression-free survival (PFS) and objective response benefit with the EGFR inhibitors.

Sequist says the PFS data from LUX-Lung 3 and LUX-Lung 6 led to the approval of afatinib in many countries. Identical results were seen between the two studies — there was no survival advantage between afatinib and chemotherapy, though patients with different 

 mutations experienced varying degrees of benefit.

View more from the 2014 Multidisciplinary Symposium in Thoracic Oncology

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6